Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease [RETIRED]
Report of the Guideline Development Subcommittee of the American Academy of Neurology
Citation Manager Formats
Make Comment
See Comments

Abstract
This guideline is retired. The recommendations and conclusions are no longer considered valid and no longer supported by the AAN. Retired guidelines should be used for historical reference only. Please see AAN current guidelines here
Footnotes
Study funding: This guideline was developed with financial support from the American Academy of Neurology. None of the authors received reimbursement, honoraria, or stipends for their participation in development of this guideline.
- Received February 13, 2012.
- Accepted in final form May 14, 2012.
- Copyright © 2012 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
- Author response
- Melissa J Armstrong, Assistant Professor of Neurology, University of Maryland[email protected]
- Janis Miyasaki, Toronto, ON, Canada
Submitted September 05, 2012 - Pharmacologic treatment of chorea in Huntington disease
- Oksana Suchowersky, Profess or Medicine - Neurology, University of Alberta [email protected]
- Edmonton, Alberta, Canada
Submitted August 28, 2012
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Clinical manifestations of intermediate allele carriers in Huntington diseaseEsther Cubo, María A. Ramos-Arroyo, Saul Martinez-Horta et al.Neurology, July 08, 2016 -
Articles
Tetrabenazine as antichorea therapy in Huntington diseaseA randomized controlled trialHuntington Study Group et al.Neurology, February 13, 2006 -
Null Hypothesis
Clinical manifestations of homozygote allele carriers in Huntington diseaseEsther Cubo, Saul-Indra Martinez-Horta, Frederic Sampedro Santalo et al.Neurology, March 13, 2019 -
Brief Communications
Effect of donepezil on motor and cognitive function in Huntington diseaseE. Cubo, K. M. Shannon, D. Tracy et al.Neurology, October 09, 2006